New Scientific Publication

We are pleased to announce our newest paper in Cancers MDPI is now published online!

This work unveils the potential of Apmonia Therapeutics’ lead candidate TAX2 (AP-01) in ovarian cancer therapy, and shows how selective antagonization of TSP-1:CD47 axis is a new powerful way of activating anti-tumor immunity.

We believe our innovative technology to be a safer and effective approach with the potential to treat multiple indications of solid tumors.


Share this post

Share on facebook
Share on linkedin
Share on twitter
Share on email

More to explore

Overall News

Welcome to Reims 2019

Apmonia Therapeutics is honored and delighted to have been elected as most promising #startup of the year during “Welcome to Reims” event last week. We